Featured Research

from universities, journals, and other organizations

Popular cancer drug can cause kidney damage, study finds

Date:
June 12, 2010
Source:
American Society of Nephrology
Summary:
The widely used cancer drug bevacizumab may cause severe loss of protein from the kidney into the urine that can lead to significant kidney damage and can compromise the efficacy of cancer treatment, according to a new study. The results suggest that physicians should monitor patients' kidney health when prescribing this angiogenesis inhibitor.

The widely used cancer drug bevacizumab may cause severe loss of protein from the kidney into the urine that can lead to significant kidney damage and can compromise the efficacy of cancer treatment, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). The results suggest that physicians should monitor patients' kidney health when prescribing this angiogenesis inhibitor.

While research indicates that treatment with the chemotherapy drug bevacizumab can lead to urinary protein leakage (proteinuria) and kidney damage, the overall risk associated with the drug and patient risk factors are unknown. Bevacizumab blocks a protein called vascular endothelial growth factor, thus inhibiting the production of new blood vessels around tumors.

Shenhong Wu MD, PhD (Stony Brook University Cancer Center), Xiaolei Zhu, MD, PhD (Kidney Doctors PLLC), and their colleagues conducted a review of published randomized, controlled clinical trials to assess the overall risk for severe proteinuria in patients taking bevacizumab. The researchers analyzed data from 16 studies comprising 12,268 patients with a variety of tumors.

Severe proteinuria occurred in 2.2% of patients taking bevacizumab. Compared with patients taking chemotherapy alone, patients taking bevacizumab combined with chemotherapy had a 4.79-fold increased risk of developing severe proteinuria and a 7.78-fold increased risk of developing nephrotic syndrome. (Nephrotic syndrome is a group of symptoms including protein in the urine, low blood protein levels, high cholesterol levels, high triglyceride levels, and swelling.)

Patients taking higher dosages of bevacizumab had the greatest risk of developing proteinuria. Also, when the investigators looked at differences by cancer type, they found that patients with kidney cancer had the highest risk of developing proteinuria (10.2% incidence).

These results indicate that it is particularly important to monitor the effects of bevacizumab in patients who have kidney cancer or who are receiving high doses of the drug. Future studies should investigate how to reduce bevacizumab's kidney-related effects, and physicians should be prepared to treat these potential side effects.

Study co-authors include Christi Kim, MD and Lea Baer, MD (Stony Brook University Cancer Center).


Story Source:

The above story is based on materials provided by American Society of Nephrology. Note: Materials may be edited for content and length.


Journal Reference:

  1. Shenhong Wu, Christi Kim, Lea Baer, and Xiaolei Zhu. Bevacizumab Increases Risk for Severe Proteinuria in Cancer Patients. Journal of the American Society of Nephrology, 2010; DOI: 10.1681/ASN.2010020167

Cite This Page:

American Society of Nephrology. "Popular cancer drug can cause kidney damage, study finds." ScienceDaily. ScienceDaily, 12 June 2010. <www.sciencedaily.com/releases/2010/06/100610171708.htm>.
American Society of Nephrology. (2010, June 12). Popular cancer drug can cause kidney damage, study finds. ScienceDaily. Retrieved September 19, 2014 from www.sciencedaily.com/releases/2010/06/100610171708.htm
American Society of Nephrology. "Popular cancer drug can cause kidney damage, study finds." ScienceDaily. www.sciencedaily.com/releases/2010/06/100610171708.htm (accessed September 19, 2014).

Share This



More Health & Medicine News

Friday, September 19, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

The Cost of Ebola

The Cost of Ebola

Reuters - Business Video Online (Sep. 18, 2014) As Sierra Leone prepares for a three-day "lockdown" in its latest bid to stem the spread of Ebola, Ciara Lee looks at the financial implications of fighting the largest ever outbreak of the disease. Video provided by Reuters
Powered by NewsLook.com
What HealthKit Bug Means For Your iOS Fitness Apps

What HealthKit Bug Means For Your iOS Fitness Apps

Newsy (Sep. 18, 2014) Apple has delayed the launch of the HealthKit app platform, citing a bug. Video provided by Newsy
Powered by NewsLook.com
U.S. Food Makers Surpass Calorie-Cutting Pledge

U.S. Food Makers Surpass Calorie-Cutting Pledge

Newsy (Sep. 18, 2014) Sixteen large food and beverage companies in the United States that committed to cut calories in their products far surpassed their target. Video provided by Newsy
Powered by NewsLook.com
Residents Vaccinated as Haiti Fights Cholera Epidemic

Residents Vaccinated as Haiti Fights Cholera Epidemic

AFP (Sep. 18, 2014) Haitians receive the second dose of the vaccine against cholera as part of the UN's vaccination campaign. Duration: 00:34 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins